|
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ERBB2IP |
Gene summary for ERBB2IP |
| Gene information | Species | Human | Gene symbol | ERBB2IP | Gene ID | 55914 |
| Gene name | erbb2 interacting protein | |
| Gene Alias | ERBB2IP | |
| Cytomap | 5q12.3 | |
| Gene Type | protein-coding | GO ID | GO:0001816 | UniProtAcc | Q96RT1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55914 | ERBB2IP | P28T-E | Human | Esophagus | ESCC | 3.28e-14 | 2.53e-01 | 0.1149 |
| 55914 | ERBB2IP | P30T-E | Human | Esophagus | ESCC | 1.56e-18 | 5.05e-01 | 0.137 |
| 55914 | ERBB2IP | P31T-E | Human | Esophagus | ESCC | 7.28e-26 | 4.30e-01 | 0.1251 |
| 55914 | ERBB2IP | P32T-E | Human | Esophagus | ESCC | 2.86e-20 | 3.81e-01 | 0.1666 |
| 55914 | ERBB2IP | P36T-E | Human | Esophagus | ESCC | 1.47e-14 | 4.56e-01 | 0.1187 |
| 55914 | ERBB2IP | P37T-E | Human | Esophagus | ESCC | 1.10e-26 | 4.90e-01 | 0.1371 |
| 55914 | ERBB2IP | P38T-E | Human | Esophagus | ESCC | 1.00e-03 | 2.20e-01 | 0.127 |
| 55914 | ERBB2IP | P39T-E | Human | Esophagus | ESCC | 2.93e-15 | 2.72e-01 | 0.0894 |
| 55914 | ERBB2IP | P40T-E | Human | Esophagus | ESCC | 6.19e-10 | 2.99e-01 | 0.109 |
| 55914 | ERBB2IP | P42T-E | Human | Esophagus | ESCC | 1.04e-17 | 4.22e-01 | 0.1175 |
| 55914 | ERBB2IP | P44T-E | Human | Esophagus | ESCC | 1.94e-12 | 3.51e-01 | 0.1096 |
| 55914 | ERBB2IP | P47T-E | Human | Esophagus | ESCC | 6.62e-20 | 3.69e-01 | 0.1067 |
| 55914 | ERBB2IP | P48T-E | Human | Esophagus | ESCC | 6.62e-20 | 4.02e-01 | 0.0959 |
| 55914 | ERBB2IP | P49T-E | Human | Esophagus | ESCC | 5.23e-14 | 8.57e-01 | 0.1768 |
| 55914 | ERBB2IP | P52T-E | Human | Esophagus | ESCC | 1.76e-12 | 2.40e-01 | 0.1555 |
| 55914 | ERBB2IP | P54T-E | Human | Esophagus | ESCC | 2.45e-13 | 3.23e-01 | 0.0975 |
| 55914 | ERBB2IP | P56T-E | Human | Esophagus | ESCC | 5.32e-14 | 7.05e-01 | 0.1613 |
| 55914 | ERBB2IP | P57T-E | Human | Esophagus | ESCC | 3.89e-12 | 2.32e-01 | 0.0926 |
| 55914 | ERBB2IP | P61T-E | Human | Esophagus | ESCC | 8.11e-12 | 3.02e-01 | 0.099 |
| 55914 | ERBB2IP | P62T-E | Human | Esophagus | ESCC | 5.83e-44 | 6.87e-01 | 0.1302 |
| Page: 1 2 3 4 5 6 |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD | ![]() |
| Colorectum | SER | ![]() |
| Colorectum | MSS | ![]() |
| Colorectum | MSI-H | ![]() |
| Colorectum | FAP | ![]() |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa046213 | Cervix | CC | NOD-like receptor signaling pathway | 41/1267 | 186/8465 | 5.90e-03 | 1.95e-02 | 1.15e-02 | 41 |
| hsa0462112 | Cervix | CC | NOD-like receptor signaling pathway | 41/1267 | 186/8465 | 5.90e-03 | 1.95e-02 | 1.15e-02 | 41 |
| hsa046212 | Lung | IAC | NOD-like receptor signaling pathway | 38/1053 | 186/8465 | 1.23e-03 | 8.24e-03 | 5.47e-03 | 38 |
| hsa0462111 | Lung | IAC | NOD-like receptor signaling pathway | 38/1053 | 186/8465 | 1.23e-03 | 8.24e-03 | 5.47e-03 | 38 |
| hsa046214 | Oral cavity | EOLP | NOD-like receptor signaling pathway | 48/1218 | 186/8465 | 2.51e-05 | 1.31e-04 | 7.70e-05 | 48 |
| hsa046215 | Oral cavity | EOLP | NOD-like receptor signaling pathway | 48/1218 | 186/8465 | 2.51e-05 | 1.31e-04 | 7.70e-05 | 48 |
| hsa046216 | Oral cavity | NEOLP | NOD-like receptor signaling pathway | 39/1112 | 186/8465 | 1.79e-03 | 7.91e-03 | 4.98e-03 | 39 |
| hsa046217 | Oral cavity | NEOLP | NOD-like receptor signaling pathway | 39/1112 | 186/8465 | 1.79e-03 | 7.91e-03 | 4.98e-03 | 39 |
| Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |